Core Viewpoint - The stock price of 加科思-B (01167) increased by 6.17% to HKD 8.09, with a trading volume of HKD 17.6587 million, following the announcement of a capital increase and equity transfer agreement [1][5] Group 1: Financial Developments - 加科思's subsidiary, 北京加科思, received a first payment of RMB 125 million from 海松资本 as part of the capital increase and equity transfer agreement, enhancing the group's cash reserves [1][5] - The influx of funds is expected to support the development of innovative cancer therapy pipelines [1][5] Group 2: Clinical Research Achievements - 加科思 announced that the clinical I/IIa study results of its self-developed KRAS G12C inhibitor, glecirasib, in combination with SHP2 inhibitor JAB-3312, were published in the prestigious medical journal, The Lancet Respiratory Medicine, which has an impact factor of 32.8 [1][5] - This publication marks the first systematic clinical data on the combination of KRAS G12C and SHP2 dual oral small molecule therapy to be featured in such a high-profile journal [1][5]